Opus Genetics, Inc. Common Stock (IRD) is a publicly traded Healthcare sector company. As of September 2, 2026, IRD trades at $3.94 with a market cap of $301.17M and a P/E ratio of -4.77. IRD moved +0.00% today. Year to date, IRD is +80.66%; over the trailing twelve months it is +211.38%. Its 52-week range spans $0.65 to $5.81. Analyst consensus is strong buy with an average price target of $11.08. Rallies surfaces IRD's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for IRD, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $3.94 |
| Market Cap | $301.17M |
| P/E Ratio | -4.77 |
| EPS | $-0.80 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.81 |
| 52-Week Low | $0.65 |
| Volume | 31.51K |
| Avg Volume | 0 |
| Revenue (TTM) | $14.20M |
| Net Income | $-49.59M |
| Gross Margin | 0.00% |
14 analysts cover IRD: 0 strong buy, 14 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $11.08.